Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims align with label-supported increased bleeding risk and monitoring with concomitant antithrombotic therapy, but many other claims (e.g., fish oil/DHA additions, GI/burping effects, specific DOAC names, bleeding disorders/history, and generalized counseling language) are not supported by the provided label excerpts.
Category Scores
Accurate Statements
VASCEPA is associated with an increased risk of bleeding, with greater incidence in patients receiving concomitant antithrombotic medications such as aspirin, clopidogrel, or warfarin.
5.3 Bleeding
Monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding.
7.1 Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents
VASCEPA is icosapent ethyl, which is an ethyl ester of EPA (eicosapentaenoic acid).
11 DESCRIPTION
Unsupported Statements
Regular fish oil supplements often contain a mix of omega-3s, typically including both EPA and DHA.
No support in the provided label excerpts.
Vascepa is specifically purified EPA, not a general fish oil blend.
The provided label excerpts identify icosapent ethyl as an EPA ethyl ester, but do not explicitly describe 'purified' or contrast against 'general fish oil blend' terminology.
Taking a standard fish oil along with Vascepa can double up on EPA and possibly add DHA on top.
No label support for dose/additive/mixture consequences of combining with fish oil supplements.
Taking additional omega-3s can increase total omega-3 intake.
No provided label support describing effects of increased total omega-3 intake.
Increasing total omega-3 intake may raise the chance of side effects such as bleeding risk in some people.
Label excerpts support increased bleeding risk with VASCEPA and higher incidence with concomitant antithrombotics; they do not support a generalized causal linkage to 'increasing total omega-3 intake' specifically.
Increasing total omega-3 intake may raise the chance of gastrointestinal upset in some people.
No provided label support.
Omega-3 products can affect platelet function to a small degree in some patients.
No provided label support for this specific characterization.
The bleeding risk concern may be relevant if a person takes blood thinners such as warfarin, apixaban, or rivaroxaban.
Warfarin is mentioned in the provided label excerpts; apixaban and rivaroxaban are not supported by the provided excerpts.
The bleeding risk concern may be relevant in people with bleeding disorders or a history of bleeding.
No provided label support.
People sometimes get more common omega-3 supplement side effects when total intake goes up.
No provided label support.
Increased total omega-3 intake may cause reflux or 'fishy' burps.
No provided label support.
Increased total omega-3 intake may cause nausea or diarrhea.
No provided label support.
Increased total omega-3 intake may cause bruising or a bleeding tendency in susceptible people.
The label excerpts support bleeding risk and monitoring with concomitant antithrombotics; they do not support bruising/bleeding tendency as a function of 'increased total omega-3 intake' or define 'susceptible people' in this way.
The safest approach is to check with a prescriber or pharmacist before combining fish oil products.
No provided label excerpt supports this generalized counseling instruction.
Contradictions
Important Omissions
No label-supported dosing/administration details were included in the AI response (not requested, but materially relevant to full prescribing accuracy).
Importance:
Low
No use-in-specific-populations information was provided (e.g., pregnancy/lactation, pediatrics), which cannot be assessed from the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Label-supported bleeding risk/monitoring with concomitant antithrombotics is reflected, but several other claims are not label-supported and could mislead regarding causality (e.g., effects attributed to 'increasing total omega-3 intake') and specific drug coverage (apixaban/rivaroxaban).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple statements are not supported by the provided label excerpts, and some broaden the label beyond supported claims (e.g., generalized effects of increasing total omega-3 intake, and naming apixaban/rivaroxaban not present in provided sections).
Suggested Improvement
Restrict safety/interactions language to label-supported points: increased bleeding risk with VASCEPA, greater incidence with concomitant antithrombotics (including aspirin/clopidogrel/warfarin per provided excerpts), and monitoring for bleeding with concomitant anticoagulant/antiplatelet therapy. Remove or qualify statements not supported by the provided label excerpts (e.g., GI/burping claims, bleeding disorders/history, apixaban/rivaroxaban, and generalized 'check with pharmacist before combining fish oil').